Adrian Bot, M.D., Ph.D. is the Vice President of Translational Medicine at Kite, a Gilead Company. Kite is a biotechnology company which developed a first generation gene therapy for cancer, based in Los Angeles, CA. He has more than 20 years of experience in biomedical research and development. Dr. Bot obtained his M.D. at the University of Medicine and Pharmacy in Timisoara – Romania and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York. Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla and Scientist, Principal Scientist and Director of Immunology Research at Alliance Pharmaceutical Corp. in San Diego. In Nov 2002, Dr. Bot joined Allecure Pharmaceuticals which became MannKind Corp, where he was a Director of Research and Development. He had several other appointments at MannKind: Senior Director of Translational Medicine, Vice President of Scientific Management and Vice President of Research, prior to the appointment as Chief Scientific Officer and then Vice President of Translational Medicine at Kite. Dr. Bot has several patents in the field, more than 150 congress abstracts and publications to date, has served or is serving on editorial boards and leading organizations such as the Society of Immunotherapy for Cancer.